Table 1.
Study | ①* | ②* | ③* | ④* | ⑤* | ⑥* | ⑦* |
---|---|---|---|---|---|---|---|
Kalem (2020) | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
Huang (2020) | Low risk | Low risk | Unclear risk | Low risk | Unclear risk | Low risk | Unclear risk |
Scarpellini (2019) | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk |
Arefi (2018) |
Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
Tanha (2016) | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk |
Aleyasin (2016) | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
Obidniak (2016) | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
Maryam (2016) | Low risk | Low risk | Unclear risk | Low risk | Unclear risk | Low risk | Unclear risk |
Abedi (2015) | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |